Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.
Risk & Volatility
Praxis Precision Medicines has a beta of 3.16, suggesting that its share price is 216% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Praxis Precision Medicines and Ionis Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Praxis Precision Medicines | 0 | 1 | 2 | 0 | 2.67 |
| Ionis Pharmaceuticals | 1 | 4 | 5 | 0 | 2.40 |
Valuation and Earnings
This table compares Praxis Precision Medicines and Ionis Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Praxis Precision Medicines | N/A | N/A | -$214.03 million | ($3.86) | -0.34 |
| Ionis Pharmaceuticals | $587.00 million | 10.40 | -$269.72 million | ($2.31) | -18.47 |
Praxis Precision Medicines has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
93.1% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 90.3% of Ionis Pharmaceuticals shares are held by institutional investors. 4.9% of Praxis Precision Medicines shares are held by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Praxis Precision Medicines and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Praxis Precision Medicines | N/A | -190.08% | -137.72% |
| Ionis Pharmaceuticals | -56.85% | -57.58% | -12.74% |
Summary
Praxis Precision Medicines beats Ionis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.jpg?v=20230511062707&h=45&w=95&zc=2){kind=logo}
